Jump to content

MaryOld

Over 2000 Posts
  • Posts

    971
  • Joined

  • Last visited

Everything posted by MaryOld

  1. From http://www.medscape.com/viewarticle/435929?srcmp=endo-060702 Young Women Often Overlook Signs of Ovarian Failure NEW YORK (Reuters Health) Jun 03 - Young women with spontaneous premature ovarian failure often overlook the menstrual signs that could be a clue to the diagnosis, according to a recent report. Approximately 1% of US women experience ovarian failure by 40 years of age, according to a statement from the National Institutes of Health. Premature ovarian failure is a well-established risk factor for osteoporosis. By ignoring menstrual signs, the diagnosis of premature ovarian failure is delayed, as is the initiation of treatments to prevent osteoporosis. "Because missed periods are common symptoms in young women, it is understandable that more than half of our patients were not concerned at first," lead investigator Dr. Lawrence Nelson, from the National Institute of Child Health and Human Development (NICHD) in Bethesda, Maryland, said in a statement. "But the delay in evaluating and treating ovarian insufficiency may place young women at increased risk of developing osteoporosis in later years," he explained. To better characterize the disease, Dr. Nelson's team interviewed 48 women who had been diagnosed with spontaneous premature ovarian failure. The mean age of the study group was 33.5 years. The most common presenting symptom was a disturbance in menstrual cycle, reported by 44 of the women, the researchers note in the May issue of Obstetrics & Gynecology. More than half of the women interviewed said they did not view missing their period as an important health issue and that they did not fully appreciate that the ovary is an important source of hormones. Forty-six percent said they felt their knowledge of menstrual health was lacking, the report indicates. More than half of the women with menstrual irregularities reported having seen three or more different physicians before being diagnosed with premature ovarian failure, and one in four of the woman said it took longer than 5 years for them to be diagnosed with the condition, the authors note. "These findings suggest that women and their physicians may want to err on the side of caution and evaluate menstrual irregularities early," Dr. Duane Alexander, director of the NICHD, said in a statement.
  2. Selected Ongoing Clinical Trials from Southern Medical Journal Evaluation of Patients With Thyroid Disorders This observational study will examine the history, clinical presentation, and genetics of thyroid function disorders. Physical examination, endocrine blood and urine tests, TRH tests, thyroid nuclear medicine scans, thyroidal radioiodine or technetium uptake measurements, X-ray, computed tomography, MRI, or other standard diagnostic procedures will be used as indicated. Men and women of any age with thyroid abnormalities are eligible for enrollment. Contact: National Institute of Diabetes and Digestive and Kidney Disease, 9000 Rockville Pike, Bethesda, MD 20892. (800) 411-1222. E-mail: prpl@mail.cc.nih.gov.
  3. WooHoo! Thanks to everyone who participates! Total disbursed so far: $106.39 Total raised through shopping: $138.07 through bonuses: $33.00 Grand total raised: $171.07
  4. ===> Extra! Extra! Read all about it! $5 Free Donation. From March 1 through June 30 2002, (extended deadline) each new member who registers at iGive and shops will earn an additional $5 for these boards. That's on top of the standard of up to 26% from their shopping. Only hitch - you've got to shop within 45 days of joining. With over 370 stores now at iGive, you've got some great choices. ===> Inkjet cartridges and toner supplies are one of the most popular items. You can save 50 - 80%! ===> Easier than falling off a log - the iGive Shopping Window! http://www.iGive.com/html/shopwindow.cfm ===> Get even more - check out Office Depot, Office Max and Viking for office supplies - get your tax exemption and get money back, when you shop via iGive.com
  5. Yes, I remember that you moderate a board, Lynn I had asked, on the "main" board, for everyone who I had listed - moderators, CUSH people, people who wanted to host a chat - to email me to get their passwords. Very few people did. I don't know if it's because they didn't read the post or not. It was the one titled something like "Board moderators Check In". I figured that was a post that moderators would read, but I was apparently mistaken. Anyway, I'll PM you the password, Lynn. Thanks for asking about it
  6. It says they're machine washable - but we'll see. Sometimes, they say that they are, and techincally they are, but they never look the same. We'll see how these go. Sue, maybe youshould get lots, so when one gets dirty, you'll alwas have a spare LOL
  7. Thanks, Sue - I'm going to order some, too, but I'm going to wait for a bit and see if I can get enough stuff to qualify for the free shipping offer. I hope to get some more things up and ready over the next week. Think that there would be any call for barbecue aprons? Here's a current list of the blank products that I can put logos on. http://www.cafepress.com/cp/info/products/index.aspx Next week, they will add the stickers, flying discs, license plate frames and wall clocks. ?I'm hoping that the stickers will be like those cling things we were talking about before. For July 4th, there will be some kind of plush eagle. ?Not sure what that will look like though.
  8. Stickers, flying discs, license plate frames and wall clocks will be available online next week, too. Would anyone be interested in any of these? Also...until June 9,
  9. Insulated Cooler Bag Great for keeping your lunch fresh and beverages cold (and urine fresh???), our handy insulated lunch bag/cooler will hold up to six 12oz cans with ice. Bag includes handy front pocket, adjustable shoulder strap and zip tight top. 100% Denier Polyester Exterior, Nylon interior Adjustable Shoulder Strap Front Pocket Note the color! Perfect for remembering those 24-hour jugs! Only $18.99 each For each cooler, $1.00 goes to CUSH and $1.00 goes to the fees for running these boards and websites. Note that this is a "limited" item, and that, like the Valentine's bears, will be discontinued at some point. I'll try to let you know in advance when that will be. Click here for more info or to order
  10. New! ?Cushie Tote Bag Our 100% cotton canvas tote bags have plenty of room to carry everything you need when you are on the go. They include a bottom gusset and extra long handles for easy carrying. 10 oz heavyweight natural canvas fabric Full side and bottom gusset 22" reinforced self-fabric handles Machine washable Just the thing for carrying those Symptoms Lists to the endo or papers at the UVA convention! Only $14.99 each. ?For each bag, $1.00 goes to CUSH and $1.00 goes to the fees for running these boards and websites For more info, or to order, click here for the Cushie Store
  11. http://www.medscape.com/viewarticle/434053 Possible Link Between CJD and Human Growth Hormone NEW YORK (Reuters Health) May 22 - Dutch researchers report the case of a man who developed Creutzfeldt-Jakob disease (CJD) 38 years after receiving a low-dose of human derived growth hormone during a diagnostic procedure. Reporting in the June issue of the Journal of Neurology, Neurosurgery, and Psychiatry, Dr. C. M. van Duijn, from Erasmus University Medical Centre Rotterdam, and colleagues describe the case of a 47-year-old man who developed paraesthesia followed by rapidly progressive ataxia. One month after presentation, the patient's condition rapidly declined and he died 5 months after hospital admission. Dr. van Duijn's team had made a clinical diagnosis of CJD, which was confirmed at necropsy. The patient's history revealed that at 9 years of age he was given 6 IU of human growth hormone over 5 days to rule out growth hormone deficiency. Dr. van Duijn's team notes that this is the second Dutch patient to die from CJD after human growth hormone treatment. In the first case, the woman had been treated with intramuscular injections of human growth hormone over several years. When the women was 39 years of age, 27 years after starting human growth hormone treatment, she developed an ataxic gate, slurred speech, sensory disorders, and myoclonus. CJD was confirmed postmortem. Based on this woman's case, a retrospective study was undertaken to find all 564 registered patients who had been treated with human growth hormone before 1985. As of January 1995, none of these subjects was suspected of having CJD, the researchers note. "An incubation period as long as 38 years had never been reported for iatrogenic CJD," Dr. van Duijn's group notes. They speculate that the long incubation period was due to the low-dose of human growth hormone the patient received. Dr. van Duijn and colleagues conclude that "since our patient was one of the first in the world to receive human growth hormone, this case indicates that still more patients with iatrogenic CJD can be expected in the coming years. Another implication of our study is that CJD can develop even after a low dose of human growth hormone." They stress that "this case once more testifies that worldwide close monitoring of any form of iatrogenic CJD is mandatory." J Neurol Neurosurg Psychiatry 2002;72:792-793.
  12. Adrienne, the person you got it from, most likely didn't even send it at all. This worm sends out it's own emails, using address books that people might have. So, it might appear that person X has sent along an email, but they're not even aware of it. Something interesting with this - my CushingsSupport email address sent a copy of this along to my PianoMary name. No way would I have sent myself a file like this! Remember - never, ever download an exe or a zip file even from someone you know unless you're absolutely, positive that they sent you this file. A good, up to date, virus scanner is a must, too.
  13. Apparently Microsoft knows that this is a security issue involving Internet Explorer. If you use this browser, to to http://www.microsoft.com/windows....ult.asp for a Security Update. 15 May 2002 Cumulative Patch for Internet Explorer (Q321232) Originally posted: May 15, 2002 Summary Who should read this bulletin: Customers using Microsoft? Internet Explorer Impact of vulnerability: Six new vulnerabilities, the most serious of which could allow code of attacker's choice to run. Maximum Severity Rating: Critical Recommendation: Consumers using the affected versions of IE should install the patch immediately. Affected Software: Microsoft Internet Explorer 5.01 Microsoft Internet Explorer 5.5 Microsoft Internet Explorer 6.0
  14. Cushing's Help and Support has only 44 days left for $5 Donation Match iGive has extended its offer of a FREE $5 bonus for each new shopper until June 30, 2002! Time is running short. Unless you spread the word Cushing's Help and Support will miss out. ============================== Contents ------------------------------ 1. $5 Bonus Information 2. Don't get left behind 3. It Adds Up Quickly 4. Hundreds of Great Deals 5. Tracking & Registration are so easy 6. Supporters get started with just one click 7. Cause Statistics ========================================= 1. FREE $5 + up to 26% of each purchase! ----------------------------------------- Each new person who registers at iGive.com between now and June 30 can raise an additional $5 for your cause, on top of earning up to 26% of each purchase for you! All they have to do is shop via iGive.com within 45 days of joining. We make it easy, with over 360 familiar stores (like Amazon, Lands' End, PetFood Direct, Office Depot, and Best Buy) to choose from! The average online shopper is earning about $20-$40 per year for their chosen cause. Some shoppers are raising that for their cause each month! Make sure that cause is Cushing's Help and Support. =============================================== 2. It's working for thousands of causes ----------------------------------------------- The average check we wrote last month was for about $75. You can see a list of recent checks we've sent at http://www.iGive.com/html/payments.cfm ======================================== 3. Benefits come quickly ---------------------------------------- Just five new shoppers can mean another $150, $200, even $500 or more in the coming year. Better yet, it continues year in and year out, without any more work on your part. ================================= 4. Hundreds of Great Deals! --------------------------------- As always, your supporters get great deals, never pay more, and might even pay less when they shop for things they need from stores they know and trust. Books, records, office supplies, clothes, pet supplies, and gifts are just some of the things people are buying every day. Why shouldn't each purchase also help Cushing's Help and Support? Even simply bidding at eBay can help your organization, when your supporters are members of iGive.com. It really is simple. All your supporters have to do to register is click on your special link. Free for them, free for you. But they'll only know about it if you spread the word! ============================================ 5. Tracking & Registration is Automatic -------------------------------------------- Whenever members shop by starting at iGive.com, our newsletter, or by using the iGive.com Shopping Window, they'll automatically be earning money for Cushing's Help and Support. Each month, we send out checks to qualifying causes. ========================================== 6. Get Started Today with this simple link ------------------------------------------ Each day that goes by means lost opportunity - wasted money. Don't let that happen. Simply by letting your supporters and friends know that they can help, without it costing anything you'll be helping Cushing's Help and Support. Your supporters can join just by clicking on this link: http://www.iGive.com/html/refer.cfm?causeid=17825 Send it to them today. The $5 bonus expires June 30, 2002. ================================== 7. Cushing's Help and Support Cause statistics & info ---------------------------------- Money raised to help support thes boards and Cushings-Help.com: $149.50 $5 Registration Bonuses: $15.00 Members: 34 Members joined since 3/1/02: 10 Statistics as of 5/12/02 and are subject to change.
  15. The American Association of Clinical Endocrinologists Calls for Patients With Diabetes to Take Charge of Their Health JACKSONVILLE, Fla., May 17 /PRNewswire/ -- New information about diabetes and the treatment of this growing nationwide epidemic can create confusion on how patients should handle their health. ?The American Association of Clinical Endocrinologists (AACE) takes a strong stand on the diabetes patients' involvement in their care. The recent study in the Journal of the American Medical Association (JAMA) which brought attention to potential side effects caused by metformin, also sold as Glucophage, is an example of this distribution of incomplete information. ?Metformin, used regularly by a very large number of patients, has shown a unique utility for patients by helping to control diabetes while maintaining or even losing weight, which is important because of the link between obesity and diabetes. ?Furthermore, extensive metformin use has been associated with a strong safety record. AACE created the Intensive Diabetes Self-Management System, which includes an AACE Patient/Physician Contract. (http://www.aace.com/pub/pf/index.php) This contract clearly outlines the physician and patient's responsibilities for living with diabetes. AACE encourages patients with diabetes to talk to their physicians about any public information about diabetes. ?"It is important for patients to understand all the benefits and side effects of medications and treatments," stated AACE president, Hossein Gharib, MD, FACE. ?"Endocrinologists, the diabetes specialists, have been educating patients as well as other physicians as to the proper use of medications including metformin." AACE is a professional medical organization with over 4,000 members in the United States and 74 other countries. ?Founded in 1991, AACE is dedicated to the optimal care of patients with endocrine problems. ?AACE initiatives inform the public about endocrine diseases. ?AACE also conducts continuing education programs for clinical endocrinologists, physicians whose advanced, specialized training enables them to be experts in the care of endocrine disease, such as diabetes, thyroid disorders, growth hormone deficiency, osteoporosis, cholesterol disorders, hypertension and obesity. For further information, visit AACE Online at http://www.aace.com. MAKE YOUR OPINION COUNT - ?Click Here ? http://tbutton.prnewswire.com/prn/11690X07136284 SOURCE ?American Association of Clinical Endocrinologists ? CO: ?American Association of Clinical Endocrinologists ST: ?Florida SU: http://www.prnewswire.com ? 05/17/2002 09:24 EDT
  16. I've been getting a lot the last week or so, too...and I've never heard of the people it's coming from, either. Usually the title is something weird, though, like "CELLSPACING". I just delete them all, too, without even opening the email.
  17. FDA Approves Bravelle™ (Urofollitropin for Injection, Purified) Ferring's New Human-Derived Follicle-Stimulating Hormone For Infertility Treatment New Highly Purified Alternative to Genetically Engineered Infertility Treatments TARRYTOWN, N.Y., May 6 /PRNewswire/ -- Ferring Pharmaceuticals, a world leader in naturally occurring protein hormones, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Bravelle™ (urofollitropin for injection, purified), a highly purified, human-derived follicle-stimulating hormone (hFSH) for the treatment of infertility. Bravelle™, in conjunction with human chorionic gonadotropin, is indicated for ovulation induction following pituitary suppression. "With the introduction of Bravelle™, Ferring has expanded its family of human-derived hormones to include a highly purified, well-tolerated hFSH with proven efficacy in ovulation induction, a critical step in many infertility treatment protocols," said Wayne Anderson, president of Ferring Pharmaceuticals. "Based on the fact that recombinant technology has shown no meaningful advantage in either efficacy or safety in the clinic, Ferring remains committed to the development of human-derived products in order to seek improvements in ovarian stimulation protocols. Ferring has submitted an application to the FDA seeking additional indications for Bravelle™ in infertility treatment. This application, which is supported by additional clinical studies, brings the total number of patients studied to 577. This application is currently under review by the FDA." A Human-Derived FSH Proven as Safe and Effective as Genetically Engineered FSH Bravelle™ was compared to follitropin beta, a recombinant FSH, in a prospective, parallel group, multicenter trial in 111 oligo-anovulatory patients undergoing ovulation induction. Patients underwent pituitary suppression with a GnRH agonist prior to being randomized to Bravelle™ SC, Bravelle™ IM or follitropin beta SC. Results showed that there were no significant differences in efficacy and safety between the treatment groups. Percentage of patients achieving: Bravelle™ SC Follitropin beta SC (n=26) (n=35) Ovulation 96.1% 85.7% Clinical pregnancy 34.6% 31.4% Continuing pregnancy 34.6% 28.6% Live birth 34.6% 17.1% In addition to the studies supporting the new drug application, Ferring has recently completed two Phase 3B clinical trials involving 24 centers. These trials evaluated the use of Bravelle™ together with Repronex® (mixed protocol), Ferring's human menopausal gonadotropin, in the same syringe, in two age groups. The first study evaluated the use of a mixed protocol in 108 women ages 18 to 33 years; the second trial evaluated 120 women ages 34 to 40 years. This is the first time a prospective, systematic clinical evaluation of single daily dose mixed protocols has been conducted anywhere in the world. Bravelle™: The Natural Choice Bravelle™ is affordably priced, an important benefit since infertility treatment is generally not fully covered by insurance. It is available for both subcutaneous and intramuscular injection. Most patients prefer SC administration because it is more convenient and causes less discomfort. Added Anderson, "Bravelle™ is ideally suited to meet the needs of infertility specialists and their patients by providing an affordable solution that combines human-derived hormone efficacy with recombinant hormone-like purity." Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe Bravelle™. Like all gonadotropins, Bravelle™ is a potent substance capable of causing mild to severe adverse reactions, including ovarian hyperstimulation syndrome (incidence of 8.2%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Background on Human-Derived Hormones The key differences in human-derived and genetically engineered infertility treatments are raw material sources and cost. Human-derived FSH treatments are highly purified follitropins extracted from the urine of postmenopausal women. By comparison, genetically engineered products are derived from the secretions from Chinese hamster ovary cells that are cultured in fetal calf or other mammalian serum, and approximate human hormones. Both are manufactured in compliance with extremely strict standards (including viral inactivation and confirmatory testing), but human-derived products are generally less expensive than their genetically engineered counterparts. About Ferring Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, markets Bravelle™, Repronex® and Novarel® in the U.S. to infertility specialists and their patients. The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 1-888-337-7464 or visit http://www.ferringusa.com. For full prescribing information contact Kelly Laban at 203-762-8833. http://tbutton.prnewswire.com/prn/11690X48271306 SOURCE Ferring Pharmaceuticals CO: Ferring Pharmaceuticals; U.S. Food and Drug Administration ST: New York SU: EXE http://www.prnewswire.com 05/06/2002 18:32 EDT
  18. There are viruses going around in email...again. Kristy just sent me a copy of one that she got. The title of this current one reads: A IE 6.0 patch and the text is: This is a IE 6.0 patch I wish you would enjoy it. Do not download the attached file (usually a .exe or a .zip). Microsoft NEVER sends out files to people - you can only download them from their websites. It's a good idea never to download email files from people you don't know...kinda like "safe sex" That particular virus is the Win32 virus (W32/Klez-G). Not something that anyone wants. Here's more about this virus from McAffee: More info and from Symantic Klez Worm Continues to Spread Home PC users should be on the lookout for worm and its variants, as reports of new infections increase. Joris Evers, IDG News Service The W32.Klez worm and its variants are still loose in the wild more than a week after the latest variant was discovered, moving antivirus software vendor Symantec to upgrade it to a level 4 virus threat on its danger scale of five. Symantec says it is receiving more than 3,000 submissions a day of W32.Klez and its variants. At the peak of the SirCam virus, in mid-2001, the company received about 1,500 daily submissions, Symantec of Cupertino, California, says in a statement. "The number of submissions warrants a level-four rating," says Andre Post, senior researcher at Symantec. "But you have to see this in perspective. The submissions are for all W32.Klez variants--W32.Klez.E and W32.Klez.H are the main two contributors to these numbers." W32.Klez.H, the latest variant of the W32.Klez mass mailer worm that first surfaced last year, was discovered on April 17. A variant of a worm contains attributes of the original, but has been altered so that it behaves differently. Updated virus signatures from leading antivirus software vendors should protect against the worm. Hitting Home Home users, not corporations, are being hit by W32.Klez, according to Post. "Based on analysis of Thursday's submissions I can say that 5 percent or less of all the submissions that we get are from corporate users. The overwhelming majority is from home users. Corporations have learned that they need to protect themselves from worms and viruses like these," he says. Marius van Oers, a virus research engineer with Network Associates in Amsterdam, says W32.Klez is spreading worldwide and is "one of the biggest virus threats today, but not historically." It's not a one-day phenomenon, he says. "It started slowly and we have seen the spread accelerate in the last week." Network Associates rates the worm "medium" risk, but that really only goes for home users, according to Van Oers, who agreed that W32.Klez finds most of its victims among home users. "We aren't worried too much about the corporate users as they work with updated virus definitions and filtering on file extensions. However, we are seeing reports from home users. The risk level for corporate users is slightly below medium, but it is certainly at medium for the home users," he says. Updated Protection Both Symantec and Network Associates advise users to check if they have recent virus definition files installed. Symantec offers a special software tool to remove the virus. W32.Klez.H arrives in an e-mail with a random subject line and message body. The sender's e-mail address can be spoofed. Once launched, the worm sends itself to all addresses it finds in the Windows address book, the database of instant-messaging program ICQ, and local files. A file from the user's system is randomly selected and sent along with the worm. W32.Klez.H also attempts to disable antivirus software and drops another virus in the user's system that tries to infect executable files there and across network filing systems, according to antivirus vendor write-ups of the worm. ~~~~~~~~~~~~~~~~~~~~ You can never get a virus by posting on the boards or attending the chats. The only way to get them is through an executable (.exe) file, usually that comes through email.
  19. Low Dose DHEA Proves Effective in Treating Physical And Mental Conditions of Hypopituitarism Study Demonstrates Effects on Skin, Hair and Behavior BETHESDA, Md., May 6 /PRNewswire/ -- Researchers in Sweden have shown that low doses of dehydroepiandrosterone (DHEA) are an effective addition to the conventional treatment of women who suffer from hypopituitarism, a condition in which the pituitary gland fails to secrete a variety of pituitary hormones into the circulation. Results of the study are published in the May issue of The Journal of Clinical Endocrinology & Metabolism. "DHEA was shown to improve both mental and physical conditions in the women," said Professor Anders Karlsson, chief investigator on the study and a researcher at the University Hospital, Uppsala, Sweden. In the randomized, double-blind, placebo-controlled study, performed at The University Hospitals in Gothenburg and Uppsala, Sweden, 38 hypopituitary women with severe androgen deficiency, aged 25-65, were treated with low, age- adjusted doses of DHEA. The trial was also followed by another six months of open treatment, at which time any of the study's participants could chose to be treated with DHEA. The researchers studied the physical and psychological effects of the treatment, including effects on skin, hair, body composition, glucose metabolism, lipoproteins, coagulation, quality of life and sexual interest/activity, and compared the results between the DHEA group, the placebo group and the open treatment. Part of the study involved quality of life questionnaires for the women and their partners. According to the women's partners, the women who took DHEA showed increased initiative, stamina, alertness and sexual relations. During the open treatment period, all of the women being treated with DHEA showed an increase in sexual interest and activity. Women in the study also experienced several physical changes from the DHEA treatments. These changes included alterations in the skin's oiliness, moisture and elasticity (53 percent); increased perspiration during physical activity (63 percent); increases in axillary and/or pubic hair (76 percent); and increased handgrip strength. The DHEA treatment did not show any effect on the women's bone turnover markers or in bone mineral density. A small and transient reduction in HDL cholesterol ("good" cholesterol) concentration occurred. "Overall, we found that DHEA had positive effects on the behavior of women with severe androgen deficiency," said Dr. Gudmundur Johannsson one of the authors on the study and a researcher at Sahlgrenska University Hospital, Gothenburg, Sweden. "The dosage of DHEA used in our study was the lowest ever reported and most of the women experienced the desired effect on hair and skin. Our findings suggest that DHEA may be an effective form of androgen replacement therapy for women with severe androgen deficiency due to hypopituitarism." The researchers also note that this study supports the use of androgen replacement in androgen-deficient hypopituitary women who have impaired well- being, despite optimal replacement with other hormones, including growth hormone and estrogen. In addition, they point out that it is not clear which androgen and which formulation should be used for replacement in women. "In our experience," they write, "DHEA as a pro-hormone metabolized locally to more potent sex steroids, might offer an effective and convenient mode of replacement." JCEM is one of four journals published by The Endocrine Society. Founded in 1916, The Endocrine Society is the world's oldest, largest, and most active organization devoted to research on hormones, and the clinical practice of endocrinology. Today, The Endocrine Society's membership consists of over 10,000 scientists, physicians, educators, nurses and students, in more than 80 countries. Together, these members represent all basic, applied, and clinical interests in endocrinology. The Endocrine Society is based in Bethesda, Maryland. To learn more about the Society, and the field of endocrinology, visit the Society's web site at http://www.endo-society.org. http://tbutton.prnewswire.com/prn/11690X64062465 SOURCE The Endocrine Society CO: The Endocrine Society ST: Maryland, Sweden SU: WOM SVY http://www.prnewswire.com 05/06/2002 12:21 EDT
  20. From: http://www.acurian.com/patient/content/detail.jsp?id=0900744b80019e0c&cd=FEATURE&camp=mlnewshtml OHSU, VAMC Researchers Reveal Benefits of Tiny Iron Particles in Brain Tumor Imaging Source:Oregon Health & Science University 04/15/2002 Iron oxide particles called ferumoxtran may also be a useful tool for tumor pathology and gene therapy research PORTLAND, Ore. -- Researchers at Oregon Health & Science University and Portland Veterans Affairs Medical Center have discovered that ultra small iron oxide particles may help improve brain tumor imaging methods. When introduced into the blood stream, these particles have the ability to help define the form of brain tumors for extended periods of time when used in conjunction with magnetic resonance imaging (MRI). In the future the use of these specially coated particles called ferumoxtran could allow neurosurgeons to better track the progress of brain tumor removal throughout the operation. Ferumoxtran also offers promising advancements in the fields of pathology and genetic therapy research. The research appears as the cover article in the April 2002 issue of the American Journal of Neuroradiology. Currently a compound called gadolinium is the standard "contrast agent" introduced intravenously into the brain in order to distinguish brain tumors from normal brain material when viewing an MRI. However, gadolinium has its shortcomings. It only works for 30 to 60 minutes before its effects dissipate. In addition, gadolinium can sometimes highlight brain material that is not diseased, but merely traumatized during surgery. In comparison, ferumoxtran particles highlight the area around the tumor, not traumatized tissue. The particles also take much more time to dissipate from the blood stream. This research showed the presence of ferumoxtran in images taken 24 hours after its infusion. This is made possible through a special glucose coating called dextran which keeps the ferumoxtran from disappearing prematurely. In fact, in previous studies using rat models, researchers found that due to this coating, ferumoxtran has the ability to remain in the brain for weeks after direct brain injection before disappearing. "Within the next few weeks, OHSU will be one of the only hospitals in the entire country with a neurosurgery suite outfitted with an MRI machine. With the use of ferumoxtran, surgeons using MRI-outfitted surgical suites might have the ability to image a tumor in the brain during the operation without repeated introduction of a contrasting agent," said senior author Edward A. Neuwelt, M.D., Portland VA Medical Center neurosurgeon and OHSU School of Medicine professor of neurology and neurosurgery. Lead author Peter Varallyay, M.D., Neuwelt and their colleagues said that in addition to the possible future benefits in the operating room, ferumoxtran may play a major role in the pathology lab. Ferumoxtran particles can be tracked as they circulate through the body. This makes it possible for pathologists to directly compare sections of diseased tissue removed from the brain and stained to reveal these iron particles with preoperative MRI images to better understand the form and function of the tumor. The ability to track ferumoxtran in the body may also benefit gene therapy research. The iron particles, which are the size of a small virus, could help determine the effectiveness of using certain viruses as vehicles to deliver therapeutic genes to areas of the human body. By tracking distribution of ferumoxtran particles, scientists would have the ability to pinpoint where these viral vectors go and whether they are reaching their targets. Using this information, scientists could then use these targeted viruses to carry therapeutic genes. This work has already begun in animal models. Researchers at OHSU are planning future research into the possible benefits of ferumoxtran as a contrast agent for other neurological diseases that involve lesions. Those diseases include multiple sclerosis, Alzheimer's disease and stroke. In addition to Neuwelt and Varallyay, co-authors of the AJNR paper include Gary Nesbit, M.D., Leslie L. Muldoon, Ph.D., Randal R. Nixon, M.D., Johnny Delashaw, M.D., James I. Cohen, M.D., Annie Petrillo, F.N.P., and Doris Rink, F.N.P. The Department of Veterans Affairs and the National Institutes of Health supported their work.
  21. From: http://www.acurian.com/patient/content/detail.jsp?id=0900744b80019e03&cd=FEATURE&camp=mlnewshtml Scientists Close in on Trigger of Insulin Resistance Source: Johns Hopkins Medical Institutions 04/15/2002 ? ? Extra sugar can cause insulin resistance in cells In experiments with fat cells, Johns Hopkins scientists have discovered direct evidence that a build-up of sugar on proteins triggers insulin resistance, a key feature of most cases of diabetes. The results underscore the importance of glycosylation - attachment of a sugar to a protein -- as a way cells control proteins' activities, the scientists report in the April 16 issue of the Proceedings of the National Academy of Sciences. The scientists found that at least two proteins involved in passing along insulin's message were unlikely to work properly when coated in extra sugar. Type 2 diabetes, the most common form in adults, occurs when muscle, fat and other tissues stop responding to insulin's signals to mop up sugar from the blood. The resulting high blood sugar, if uncontrolled, can lead to blindness, amputation and death. Understanding sugar's precise influence on insulin's activity may help improve treatment and prevention, scientists hope. "Cells don't respond to insulin itself. Instead, a whole cascade of events, set in motion by insulin, eventually causes cells to take in sugar," explains Gerald Hart, Ph.D., professor and director of biological chemistry in the school's Institute for Basic Biomedical Sciences. "We now have an explanation of how sugar can affect these signals, and even a hypothesis for how high blood sugar could cause tissue damage in diabetes -- by improperly modifying proteins." Hart's lab discovered 18 years ago that sugar is used routinely inside cells to modify proteins, turning them on and off. The more commonly known protein-controller, phosphate, actually binds to some of the same building blocks of proteins as sugar does. If proteins have too many sugars on them, they can't be controlled properly by the cell and are unlikely to work correctly, suggests Hart. "We think we've come across a major mechanistic reason for insulin resistance," says Hart. "These cells developed insulin resistance simply because their proteins, and specific proteins in fact, had more than the normal number of sugar tags." If key proteins laden with sugar are present in patients with diabetes, the findings may provide a target for developing new strategies to deal with this growing public health threat, says Hart. While diabetes can be fairly well controlled by diet and carefully monitoring one's blood sugar levels, finding a way to remove extra sugar tags may help treat or prevent diabetes someday, the researchers suggest. "Textbooks frequently and incorrectly show glycosylation only happening to proteins on the cell surface," says Hart. "Complex sugars are added only to proteins outside the cell, but simple sugars are used all the time in the nucleus and cytoplasm to modify proteins. It's this glycosylation that happens inside the cell, involving simple sugars, that is the key in insulin resistance." The "simple sugar" to which he refers is O-linked beta-N-acetylglucosamine, a complex name that condenses to a difficult acronym -- O-GlcNAc -- with an ugly pronunciation -- "oh-gluck-nack." But in many ways, O-GlcNAc is a beautiful and mysterious thing, says Hart. "O-GlcNAc is a modifier on many proteins, but if you didn't know to look for it, you'd never find it," he says. "Instruments and the usual laboratory methods have a hard time measuring it, so we developed the techniques to detect it." O-GlcNAc is added to proteins by one enzyme and removed from proteins by another. By selectively blocking that removal, the scientists hoped to load up proteins with sugar without adding extra sugar (the way other scientists have created insulin resistance). "We wanted to see the effect of glycosylation itself, so we used a molecular sledgehammer to increase the amount of sugar bound to proteins," says Hart, whose lab proved the ability of the blocker, a molecule called PUGNAc. Not only did the blocker increase the amount of O-GlcNAc bound to proteins, but that increase caused the cells to stop responding to insulin, say co-first authors and postdoctoral fellows Lance Wells and Keith Vosseller. Looking for proteins in the insulin-signaling pathway that were more glycosylated than normal, Vosseller and Wells found two: beta-catenin and insulin receptor substrate-1 (IRS-1). The crucial role these proteins play in passing along insulin's messages is likely to be adversely affected by the extra sugars they carry, the researchers say. "Our experiments show that increasing O-GlcNAc on proteins is, by itself, a cause of insulin resistance, rather than an effect or a coincidence," says Vosseller. In the body, sugar (glucose) is changed into glucosamine, which is changed into O-GlcNAc. Other scientists have shown that giving cells or animals excessive amounts of sugar or glucosamine, along with extra insulin, leads to insulin resistance. The new findings provide an explanation for others' experience with animal and laboratory models of insulin resistance. There has been little study of glucosamine, a commonly used dietary supplement, in people. It is suggested that people taking glucosamine consult their doctors if they are concerned about the possibility of increasing their risk of developing diabetes.
  22. Just moving up. Thanks to the 29 iGive members from here, I'm able to defray some of the costs of running this site. Much appreciated
  23. [Official Title: Tumors of the Pituitary Gland and Associated Conditions: A Genetic Investigation Further Study Details: There is a variety of tumors affecting the pituitary gland. The gene(s) involved in the pathogenesis of these tumors are largely not known; their possible association with other developmental defects or inheritance pattern(s) has not been investigated. The present study serves as a (i) screening/training, and (ii) a research protocol. As a screening and training study, this protocol allows our Institute to admit patients with tumors of the hypothalamic-pituitary unit to the clinics and wards of the NIH Clinical Center for the purposes of: (i) training our fellows and students in the identification of gene defects associated with pituitary tumor formation, and (ii) teaching our fellows and students the recognition, management and complications of pituitary tumors. As a research study, this protocol aims at (i) developing new clinical studies for the recognition and therapy of pituitary tumors; as an example, two new studies have emerged within the context of this protocol: (a) investigation of a new research magnetic resonance imaging (MRI) tool and its usefulness in the identification of pituitary tumors, and ( investigation of the psychological effects of cortisol secretion in pediatric only patients with Cushing disease. Continuation of this protocol will eventually lead to new, separate protocols that will address all aspects of diagnosis of pituitary tumors and their therapy in childhood; and (ii) identifying the genetic components of pituitary oncogenesis; those will be investigated by (a) studying the inheritance pattern of pituitary tumors in childhood and their possible association with other conditions in the families of the patients, and ( collecting tumor tissues and examining their molecular genetics. As with the clinical studies, the present protocol may help generate ideas for future studies on the treatment an clinical follow up of patients with tumors of the pituitary gland and, thus, lead to the development of better therapeutic regimens for these neoplasms. Eligibility Genders Eligible for Study: Both Criteria INCLUSION CRITERIA: A. The following criteria must be met for all, who enter the study: Age 3-70 years Evidence for the existence of a tumor of the hypothalamic-pituitary unit, as indicated by previously obtained imaging studies or biochemical investigation of the hypothalamo-hypophyseal function. Patients may withdraw from the study at any time. B. For family members studied for linkage analysis, the following criteria must be met: Any age Member of a kindred suspected of having an inherited form of pituitary neoplasia, as evidenced by results of a patient studied under A (above). Expected Total Enrollment: 1200 Location and Contact Information Maryland National Institute of Child Health and Human Development (NICHD), 9000 Rockville Pike Bethesda, Maryland, 20892, United States; Recruiting Patient Recruitment and Public Liaison Office, 1-800-411-1222 prpl@mail.cc.nih.gov TTY 1-866-411-1010 More Information Detailed Web Page Publications Stratakis CA, Jenkins RB, Pras E, Mitsiadis CS, Raff SB, Stalboerger PG, Tsigos C, Carney JA, Chrousos GP. Cytogenetic and microsatellite alterations in tumors from patients with the syndrome of myxomas, spotty skin pigmentation, and endocrine overactivity (Carney complex). J Clin Endocrinol Metab. 1996 Oct;81(10):3607-14. Stratakis CA, Carney JA, Lin JP, Papanicolaou DA, Karl M, Kastner DL, Pras E, Chrousos GP. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest. 1996 Feb 1;97(3):699-705. Schrock E, du Manoir S, Veldman T, Schoell B, Wienberg J, Ferguson-Smith MA, Ning Y, Ledbetter DH, Bar-Am I, Soenksen D, Garini Y, Ried T. Multicolor spectral karyotyping of human chromosomes. Science. 1996 Jul 26;273(5274):494-7. Study ID Numbers 970076; 97-CH-0076 Date study started February 13, 1997 Record last reviewed, March 5, 2001 Last Updated, March 5, 2001 NLM Identifier NCT00001595 ClinicalTrials.gov processed this record on 2002-04-23
  24. Available now at http://www.CUSH.org/pins.htm Thanks Cookie and Sue!
  25. From NIH Clinical Trials listings Search term: CUSHING'S Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome Condition: Cushing's Syndrome New Imaging Techniques in the Evaluation of Patients with Ectopic Cushing's Syndrome Condition: Cushing's Syndrome Study of Cushing's Syndrome Not Related to ACTH Production Conditions: Cushing's Syndrome; Healthy Study of Depression, Peptides, and Steroids in Cushing's Syndrome Condition: Cushing's Syndrome Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome Condition: Cushing's Syndrome Long Term Post Operative Follow-Up of Cushing Syndrome Condition: Cushing Syndrome Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients with Adrenal Insufficiency Conditions: Adrenal Gland Hyperfunction; Adrenal Gland Hypofunction; Cushing's Syndrome; Healthy Genetic Investigation of Pediatric Tumors of the Pituitary Gland Conditions: Abnormalities; Craniopharyngioma; Cushing's Syndrome; Endocrine Disease; Pituitary Neoplasm Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex Conditions: Cushing's Syndrome; Hereditary Neoplastic Syndrome; Lentigo; Neoplasm; Testicular Neoplasm Bone Mineral Density in Patients with Major Depression Conditions: Healthy; Involutional Depression; Osteoporosis Dynamics of Leptin and Endocrine Function Conditions: Healthy; Involutional Depression Serotonin Receptor Imaging in Mood Disorders Condition: Mood Disorder Study of Adrenal Gland Tumors Condition: Adrenal Gland Neoplasm Search term: ADRENAL Catecholamine Reserve and Exercise Tolerance in Healthy Volunteers and Patients with Congenital Adrenal Hyperplasia Conditions: Congenital Adrenal Hyperplasia; Healthy Three Drug Combination Therapy versus Conventional Treatment of Children with Congenital Adrenal Hyperplasia Conditions: Congenital Adrenal Hyperplasia; Growth Disorder Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients with Adrenal Insufficiency Conditions: Adrenal Gland Hyperfunction; Adrenal Gland Hypofunction; Cushing's Syndrome; Healthy Study of Adrenal Gland Tumors Condition: Adrenal Gland Neoplasm Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Conditions: stage IV adrenocortical carcinoma; recurrent adrenocortical carcinoma Congenital adrenal hyperplasia: Calcium channels as therapeutic targets Condition: Congenital Adrenal Hyperplasia Study of Cushing's Syndrome Not Related to ACTH Production Conditions: Cushing's Syndrome; Healthy Diagnostic Study of Adrenal Cortical Function in Children With Septic Shock Condition: Septic Shock Brain Imaging of Childhood Onset Psychiatric Disorders, Endocrine Disorders and Healthy Children Conditions: Autoimmune Disease; Congenital Adrenal Hyperplasia; Healthy; Mental Disorder Diagnosed in Childhood; Neurologic Manifestations Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Conditions: childhood soft tissue sarcoma; childhood liver cancer; adult soft tissue sarcoma; head and neck cancer; adult primary liver cancer; thyroid cancer; Heart Disease Risk Factors in Major Depression Conditions: Adrenal Gland Hyperfunction; Cardiovascular Disease; Involutional Depression Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex Conditions: Cushing's Syndrome; Hereditary Neoplastic Syndrome; Lentigo; Neoplasm; Testicular Neoplasm New Imaging Techniques in the Evaluation of Patients with Ectopic Cushing's Syndrome Condition: Cushing's Syndrome Study of Depression, Peptides, and Steroids in Cushing's Syndrome Condition: Cushing's Syndrome Asthma Clinical Research Network (ACRN) Conditions: Asthma; Lung Diseases Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer Conditions: stage III prostate cancer; adenocarcinoma of the prostate Once-A-Month Steroid Treatment for Patients with Focal Segmental Glomerulosclerosis Conditions: Glomerulonephritis; Nephrotic Syndrome Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation Conditions: I Cell Disease; Fucosidosis; Globoid Cell Leukodystrophy; Adrenoleukodystrophy; Mannosidosis; Niemann-Pick Disease; Pulmonary Complications; Study of Glyceryl Trierucate and Glyceryl Trioleate (Lorenzo's Oil) Therapy in Male Children with Adrenoleukodystrophy Condition: Adrenoleukodystrophy Study of Oral Cholic Acid in Patients With Inborn Errors of Bile Acid Synthesis Conditions: Infantile Refsum's Disease; Zellweger Syndrome; Hyperpipecolic Acidemia; Adrenoleukodystrophy; Peroxisomal Disorders; Cholestasis; Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome Condition: Cushing's Syndrome Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome Condition: Cushing's Syndrome Study of Prevalence and Clinical Phenotype in Patients With Glucocorticoid-Remediable Aldosteronism Condition: Hyperaldosteronism Study of Bile Acids in Patients With Peroxisomal Disorders Conditions: Infantile Refsum's Disease; Zellweger Syndrome; Bifunctional Enzyme Deficiency; Adrenoleukodystrophy Genetic Investigation of Pediatric Tumors of the Pituitary Gland Conditions: Abnormalities; Craniopharyngioma; Cushing's Syndrome; Endocrine Disease; Pituitary Neoplasm Long Term Post Operative Follow-Up of Cushing Syndrome Condition: Cushing Syndrome Ovarian Follicle Function in Patients with Premature Ovarian Failure Conditions: Amenorrhea; Hypoaldosteronism; Hypogonadism; Infertility; Premature Ovarian Failure 131MIBG to Treat Malignant Pheochromocytoma Condition: Pheochromocytoma Treatment of Mid-Life-Related Mood Disorders Conditions: Depressive Disorder; Mood Disorder Diagnosis of Pheochromocytoma Condition: Pheochromocytoma Dynamics of Leptin and Endocrine Function Conditions: Healthy; Involutional Depression Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism with and without Estrogen and Progesterone Replacement Condition: Hypogonadism Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer Conditions: stage IV prostate cancer; adenocarcinoma of the prostate; recurrent prostate cancer Comparison of Radiation Therapy Plus Hormone Therapy, Radiation Therapy Alone, and Hormone Therapy Alone in Treating Patients With Stage III Prostate Cancer Condition: stage III prostate cancer Evaluation of Patients with Endocrine-Related Conditions Conditions: Endocrine Disease; Glucose Intolerance; Hyperinsulinemia; Impaired Glucose Tolerance; Non Insulin Dependent Diabetes Mellitus; Obesity; Comparison of Hormone Therapy Regimens in Treating Men With Stage IV Prostate Cancer Conditions: stage IV prostate cancer; adenocarcinoma of the prostate; recurrent prostate cancer Leuprolide Acetate (Lupron) for the Treatment of Menstrually-Related Mood Disorders (MRMD) Conditions: Depressive Disorder; Mood Disorder Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer Conditions: stage II prostate cancer; stage III prostate cancer; stage IV prostate cancer; adenocarcinoma of the prostate; recurrent prostate cancer Bone Mineral Density in Patients with Major Depression Conditions: Healthy; Involutional Depression; Osteoporosis Complementary Naturopathic Medicine for Periodontitis Condition: Periodontitis Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle Conditions: Hypogonadism; Precocious Puberty Endocrine Studies of Healthy Children Condition: Healthy Genetic Studies of Insulin and Diabetes Conditions: Diabetes Mellitus; Insulin Resistance Serotonin Receptor Imaging in Mood Disorders Condition: Mood Disorder Search term: PITUITARY Genetic Investigation of Pediatric Tumors of the Pituitary Gland Conditions: Abnormalities; Craniopharyngioma; Cushing's Syndrome; Endocrine Disease; Pituitary Neoplasm Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy Conditions: ACTH-producing pituitary tumor; somatostatinoma; nonfunctioning pituitary tumor; TSH producing pituitary tumor; Evaluation of Patients with Thyroid Disorders Conditions: Hyperthyroidism; Hypothyroidism; Pituitary Neoplasm The Treatment and Natural History of Acromegaly Conditions: Acromegaly; Pituitary Neoplasm Sandostatin LAR Depot vs. Surgery for Treating Acromegaly Conditions: Acromegaly; Pituitary Neoplasm Evaluation of Factors in Human Brain Tumors Conditions: Brain Neoplasm; Glioblastoma; Glioma; Pituitary Neoplasm Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome Condition: Cushing's Syndrome Leuprolide Acetate (Lupron) for the Treatment of Menstrually-Related Mood Disorders (MRMD) Conditions: Depressive Disorder; Mood Disorder New Imaging Techniques in the Evaluation of Patients with Ectopic Cushing's Syndrome Condition: Cushing's Syndrome Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients with Adrenal Insufficiency Conditions: Adrenal Gland Hyperfunction; Adrenal Gland Hypofunction; Cushing's Syndrome; Healthy Effects on the Brain of Lupron Induced Hypogonadotropic Hypogonadism with and without Estrogen and Progesterone Replacement Condition: Hypogonadism Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex Conditions: Cushing's Syndrome; Hereditary Neoplastic Syndrome; Lentigo; Neoplasm; Testicular Neoplasm Long Term Post Operative Follow-Up of Cushing Syndrome Condition: Cushing Syndrome An Endocrine Model for Postpartum Mood Disorders Conditions: Depressive Disorder; Mood Disorder; Postpartum Depression Antineoplaston Therapy in Treating Patients With Brain Tumors Condition: brain tumor Dynamics of Leptin and Endocrine Function Conditions: Healthy; Involutional Depression Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Conditions: Diabetes Insipidus; Diabetes Insipidus, Neurohypophyseal Study of Depression, Peptides, and Steroids in Cushing's Syndrome Condition: Cushing's Syndrome Leuprolide in Determining the Cause of Gonadotropin Deficiency Condition: Hypogonadism Randomized Study of Growth Hormone on Bone Mineral Density in Patients With Adult Onset Growth Hormone Deficiency Conditions: Osteoporosis; Growth Hormone Deficiency Complementary Naturopathic Medicine for Periodontitis Condition: Periodontitis Combined Hormone Replacement in Menstrually Related Mood Disorders Condition: Premenstrual Syndrome Study of Recombinant Human Insulin-Like Growth Factor I in Patients with Severe Insulin Resistance Conditions: Insulin Resistance; Hyperglycemia Androgen Replacement Therapy in Women with Hypopituitarism Condition: Hypopituitarism Measurement of Outcome of Surgical Treatment in Patients With Acromegaly Condition: Acromegaly Genetic Studies of Insulin and Diabetes Conditions: Diabetes Mellitus; Insulin Resistance Studies of Inherited Diseases of Metabolism Conditions: Hypercalcemia; Hyperparathyroidism; Multiple Endocrine Neoplasia Study of Gonadotropin-Releasing Hormone Pulse Frequency in Sexual Maturation and in the Menstrual Cycle Conditions: Hypogonadism; Precocious Puberty Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome Condition: Cushing's Syndrome Serotonin Receptor Imaging in Mood Disorders Condition: Mood Disorder Study of Adrenal Gland Tumors Condition: Adrenal Gland Neoplasm Leptin to Treat Severe Insulin Resistance - Pilot Study Condition: Syndrome Congenital adrenal hyperplasia: Calcium channels as therapeutic targets Condition: Congenital Adrenal Hyperplasia Search term: CARNEY COMPLEX Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex Conditions: Cushing's Syndrome; Hereditary Neoplastic Syndrome; Lentigo; Neoplasm; Testicular Neoplasm Search term: ECTOPIC New Imaging Techniques in the Evaluation of Patients with Ectopic Cushing's Syndrome Condition: Cushing's Syndrome Study of Adrenal Gland Tumors Condition: Adrenal Gland Neoplasm Jugular Vein Sampling for Hormone Levels for the Diagnosis of Cushing Syndrome Condition: Cushing's Syndrome
×
×
  • Create New...